What is the official ID of this bill?

The official print number for this legislation is HR 597.

When did the legislative process begin?

The process officially started on 2021-01-28.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/117/bills/hr597/BILLS-117hr597ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

Who is the primary sponsor?

The primary sponsor is Rep. Schakowsky, Janice D. [D-IL-9].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

Analysis and Potential Impact of HR 597

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Affordable COVID-19 Drugs: Ending Monopolies and Price Gouging.

Q: What are the main provisions?

Key points include: COVID-19 drugs developed with federal support must be affordable and accessible to all. Pharmaceutical companies cannot create monopolies or price gouge for COVID-19 drugs if they received federal support. The government can grant licenses for drug production if original manufacturers refuse to ensure broad access. Companies must report their expenditures on research, development, and marketing of COVID-19 drugs, including federal support received. In cases of excessive drug pricing during a public health emergency, the government can revoke market exclusivity and allow other companies to produce.

This act aims to ensure that COVID-19 drugs developed with government support are affordable and accessible to everyone. It means companies cannot create monopolies or artificially inflate prices, protecting citizens from excessive treatment costs and ensuring broad access to essential therapies.

Key points

COVID-19 drugs developed with federal support must be affordable and accessible to all.

Pharmaceutical companies cannot create monopolies or price gouge for COVID-19 drugs if they received federal support.

The government can grant licenses for drug production if original manufacturers refuse to ensure broad access.

Companies must report their expenditures on research, development, and marketing of COVID-19 drugs, including federal support received.

In cases of excessive drug pricing during a public health emergency, the government can revoke market exclusivity and allow other companies to produce.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Pandemic Treatment Access and Affordability Act of 2021

Print number: HR 597

Sponsor: Rep. Schakowsky, Janice D. [D-IL-9]

Process start date: 2021-01-28

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch

Affordable COVID-19 Drugs: Ending Monopolies and Price Gouging.

Key Questions about Affordable COVID-19 Drugs: Ending Monopolies and Price Gouging.